Search

Displaying results 4811 - 4820 of 8010 in total
  1. Drug

    Zilpaterol

    go.drugbank.com/drugs/DB11479
    ExperimentalVet approved

    Zilpaterol is typically fed to cattle in the last three to six weeks of life with a brief washout period to clear the drug from the tissues before slaughter. … Zilpaterol is a β2 adrenergic agonist sold under the trade name, Zilmax, produced by Intervet, a subsidiary of Merck & Co.

  2. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

  3. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  4. Drug

    gp209-2M antigen

    go.drugbank.com/drugs/DB17462
    Investigational

    The gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.

  5. Drug

    EXOB-001

    go.drugbank.com/drugs/DB18257
    Experimental

    EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.

  6. Drug

    Danofloxacin

    go.drugbank.com/drugs/DB11393
    ExperimentalVet approved

    Danofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.

  7. Drug

    S-adenosyl-L-homocysteine

    go.drugbank.com/drugs/DB01752
    Experimental

    Formed from S-adenosylmethionine after transmethylation reactions.

  8. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    It is being developed by Ascent Therapeutics. … Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia.

  9. Drug

    Tranilast

    go.drugbank.com/drugs/DB07615
    Investigational

    Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

  10. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested.